Macrophage differentiation and signal responses are coordinated by closely linked transcriptional and epigenomic mechanisms that trigger gene expression. In contrast to well-characterized transcriptional activation pathways in response to diverse metabolic and inflammatory signals, we just begin appreciating that transcriptional repression is equally important. Here, we will highlight macrophage pathways that are controlled by multifaceted repression events, along with a discussion of underlying regulatory mechanisms and components. We will particularly discuss pro-versus anti-inflammatory action of a fundamental corepressor complex, transcription factor cross-talk, repression at enhancers and during elongation, and diverse corepressor knockout mouse models. We will finally emphasize how alterations of macrophage repression pathways in humans contribute to, or even cause, metabolic inflammatory diseases such as obesity and type 2 diabetes.
Macrophage differentiation and signal responses are coordinated by closely linked transcriptional and epigenomic mechanisms that trigger gene expression. In contrast to well-characterized transcriptional activation pathways in response to diverse metabolic and inflammatory signals, we just begin appreciating that transcriptional repression is equally important. Here, we will highlight macrophage pathways that are controlled by multifaceted repression events, along with a discussion of underlying regulatory mechanisms and components. We will particularly discuss pro-versus anti-inflammatory action of a fundamental corepressor complex, transcription factor cross-talk, repression at enhancers and during elongation, and diverse corepressor knockout mouse models. We will finally emphasize how alterations of macrophage repression pathways in humans contribute to, or even cause, metabolic inflammatory diseases such as obesity and type 2 diabetes.
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Key components required for the regulation of gene expression in macrophages
Macrophages are versatile immune cells that can acquire specialized functions at particular tissue locations and in response to diverse signals. Their plasticity is reflected by the different phenotypes that they can harbor. Stimulation of macrophages with bacterial components (e.g., lipopolysaccharide, LPS), Th1 cytokines (e.g., interferon gamma, IFNc), or tissuederived factors (e.g., tumor necrosis factor alpha, TNFa) promotes maturation of classically activated M1 macrophages. These cells are characterized by secretion of interleukin (IL)-12 and IL-23, production of toxic intermediates (e.g., reactive oxygen species), and high capacity to present antigens. In contrast, various signals including IL-4, IL-13, and glucocorticoids induce alternative M2 activation of macrophages to trigger anti-inflammatory responses, promote angiogenesis, tissue remodeling, and wound healing. In line with the current understanding of macrophage heterogeneity, this commonly applied distinction of M1 (proinflammatory) and M2 (anti-inflammatory) phenotypes are the extremes of a continuum of distinct functional states. Thus, newer classifications recommend distinction of macrophage states related to host defense (close to the M1 phenotype with microbicidal activity), wound healing (promoted by IL-4 produced by Th2 cells), and immune regulation (preferentially induced by IL-10 produced by Tregs) [1, 2] .
Alterations in gene expression regulate the macrophage phenotype and polarization state. The primary response of macrophages to diverse signals occurs at the level of transcription, specifically by altering the synthesis rate of thousands of protein-coding mRNAs and noncoding RNAs (for simplicity referred to as 'gene expression'). Regulation of gene expression is triggered by closely linked epigenomic and transcriptional reprogramming events, fundamental processes that also underlie human diseases. Transcription factors (TFs, > 1500 in total, hundreds likely expressed in macrophages) and associated chromatin-modifying coregulators (> 300 to thousands in total, a majority likely expressed in macrophages) play central regulatory roles in these processes, as they shape the chromatin landscape (i.e., the epigenome) and thereby determine cellular identity and signal responses [3] . Figure 1 highlights the key components discussed in this chapter.
Genome-wide studies in mouse macrophages have started to investigate the relationship of TF and coregulator binding (cistromes), chromatin modifications (epigenomes), and gene expression (transcriptomes) [4] [5] [6] [7] [8] [9] [10] [11] . Most of the current data are derived from studies utilizing bone marrow-derived macrophages (BMDMs) or thioglycollate-elicited peritoneal macrophages (TEPMs), while the analysis of tissue macrophages has remained a challenge largely due to the limited cell number as compared to BMDMs and TEPMs. Usually, nonstimulated conditions were compared with responses to diverse inflammatory signals, including TLR 4 agonists (LPS, KLA), IFNc, TNFa, all of which trigger the M1 phenotype, and IL 4/13, triggering the alternative M2 phenotype. These studies not only emphasize the diverse roles of functionally distinct classes of TFs but also the extensive cross-talk between Highlighted are chromatin, protein, RNA, and DNA components that regulate transcription in response to metabolic and inflammatory signaling inputs via multiple mediators. There are very complex interactions between all components, in particular, different levels of positive and negative TF cross-talk. Many details are still unknown, such as how many different TFs and coregulators exactly occupy a given enhancer and which changes on the TF-coregulator composition occur during signaling-dependent activation versus repression. them. First, lineage-determining 'pioneer' TFs, such as purine-rich (PU)-box TF PU.1 and CCAAT/enhancerbinding proteins (C/EBPs), are necessary to establish macrophage-specific enhancers that control macrophage identity. Second, a large number of signal-regulated TFs regulate distinct macrophage phenotypes via the coordination of inflammatory gene expression pathways in response to distinct signaling inputs. These include members of the activator protein 1 (AP-1, for example, c-Fos, c-Jun, JunB, ATFs), interferon regulatory factor (IRF), signal transducer and activator of transcription (STAT), and nuclear factor kappa B (NF-jB, for example, p65/RelA, p50) families. Among the key metabolic TFs in macrophages are members of the nuclear receptor family as well as sterol regulatory element-binding proteins [12] [13] [14] . Transcriptomic profiling suggests that more than half of all nuclear receptor family members are expressed in macrophages [15] , including liver X receptors (LXRs), peroxisome proliferator-activated receptors (PPARs), retinoid receptors (RXRs and RARs), and glucocorticoid receptor (GR). These receptors, including their synthetic or endogenous macrophage-derived ligands (e.g., oxysterols, prostaglandin D2 metabolites, and oxidized low-density lipoprotein-derived fatty acids) are particularly important regulators of gene expression programs linked to differentiation, polarization, and metabolism in macrophages. Additionally, they all exert potent anti-inflammatory activities via transcriptionally repressing proinflammatory gene expression in the context of pathogen infections or in the context of metabolic disease conditions [12, 16, 17] .
Coregulators have two key functions. Firstly, they recognize distinct TF activity states [often altered conformations regulated by ligands and/or signaling-dependent reversible post-translational modifications (PTMs)], and secondly, they establish interactions with the transcriptional machinery and chromatin [3, 18] . They are usually classified as coactivators, when they recognize the active TF state and promote transcription, or as corepressors, when they recognize the inactive TF state and repress transcription. However, in many cases this distinction does not truly reflect the in vivo situation, since the positive or negative role of coregulators, and of their target TFs, is highly context dependent. Most coregulators function in larger multiprotein complexes to establish cell type-and ligand-dependent epigenomes by 'writing', 'erasing', or 'reading' reversible epigenetic chromatin modifications linked to transcription (e.g., acetylation/deacetylation or methylation/ demethylation of histone tails). Evidence is emerging that alterations in function or expression of coregulators cause disease by propagating disease-specific epigenomes linked to dysregulation of transcription, but most of the underlying mechanisms remain to be elucidated. This of particular relevance to understand how epigenome alterations in macrophages contribute to metabolically driven inflammatory diseases such as obesity, type 2 diabetes, fatty liver disease, and cardiovascular disease (discussed further below). Of note, the term 'metaflammation' was originally coined to describe this disease-linked state of low-grade/chronic/cold inflammation [19] .
To appreciate the impact of diverse coregulators on gene expression in macrophages, it has to be noted that many of them act as shared components of metabolic and inflammatory signaling pathways by associating with the distinct TFs regulating these pathways, such as nuclear receptors and proinflammatory TFs [12] . This not only forms the molecular basis for extensive transcriptional cross-talk and allows coregulators to modulate and redirect complex gene expression programs it also complicates the interpretation of experimental loss-and gain-of-function approaches aimed at identifying the true in vivo role of these proteins. Common to classic models of TF function is the postulation of a corepressor to coactivator switch during the transition from inactive/repressed into active chromatin states, that along with changes in histone modifications (e.g., acetylation and methylation) triggers transcriptional initiation and elongation. These transitions are triggered or accompanied by signaling-dependent regulation of cytoplasmic-nuclear shuttling, DNA binding, PTMs, and protein-protein interactions (PPIs), necessary for TF cross-talk and coregulator recruitment and dismissal [3] .
Equally important but currently less understood and appreciated is the reversibility of these processes, necessary for the distinct facets of transcriptional repression, limiting gene expression, establishing gene silencing and feedback regulation in signaling pathways [18] . For example, it is commonly assumed that corepressors interact with inflammatory TFs in the basal (noninduced) state to prevent their activation, thereby putting a molecular break on inflammation. Many pro-inflammatory TFs (e.g., p65, IRFs, STATs, c-jun) are regulated at the level of signaling/PTMinduced DNA binding, thus do not occupy chromatin in the absence of signals and may not serve as a molecular beacon for the recruitment of corepressors prior to signaling. TF-independent chromatin docking was suggested following the observation that various corepressors bind directly to hypo-acetylated histone tails [20] [21] [22] .
There are a growing number of examples suggesting that corepressors participate in signal-induced activation and associate with active enhancers (discussed further below). Moreover, the assumption that corepressors are released upon signal activation and replaced by coactivators has been experimentally validated only for few selected inflammatory genes but not on the genome-wide scale. In other contexts, for example, during adipocyte differentiation, some of the same corepressors (e.g., nuclear receptor corepressor NCOR, histone deacetylase HDAC3) occupy active enhancers along with TFs that play roles in both adipocytes and macrophages (PU.1, C/EBP, AP-1) [23] . Therefore, in many signaling contexts that are well characterized in terms of activation, our detailed understanding of repression and the composition of TF-corepressor complexes at promoter and enhancer regions is currently lagging behind.
Repression by TF cross-talk: antiinflammatory mechanisms beyond transrepression
Early studies have revealed that more than half of all nuclear receptor family members are expressed in macrophages [15] , and some of them have been reproducibly demonstrated to inhibit proinflammatory gene expression in many contexts. Figure 2 highlights the involvement of various nuclear receptors in antiinflammatory repression pathways discussed in this chapter.
Anti-inflammatory repression via TF cross-talk is often termed 'transrepression', since most data suggested that repression occurs 'in trans', that is, without direct binding of nuclear receptors to DNA response elements [12] . The investigation of the GR, along with the development of potent synthetic immunosuppressive GR ligands, has particularly advanced our molecular understanding of the underlying mechanisms. Models of action are constantly evolving [24, 25] and involve direct interactions of GR with proinflammatory TFs, corepressors such as GRIP1 (also known as SRC2, TIF2, NCOA2) [26] , and DNA response elements [27] , the latter challenging the initial concept of transrepression.
Lipid-sensing receptors such as PPARs (receptors for fatty acids) and LXRs (receptors for oxysterols) have additionally emerged as potent inhibitors of inflammatory processes [12, 16] . These metabolic regulators appear particularly suited in sensing metabolic states, allowing them to control multiple pathways involved in cholesterol, fatty acid and glucose homeostasis. Modification by small ubiquitin-like modifier SUMO (SUMOylation) targets many TFs and coregulators and has been generally linked to transcriptional repression in many cell types [28] . In macrophages, SUMOylation of LXRs and PPARc appears to be required for transrepression [29] . Of particular interest was the demonstration that SUMOylated receptors dock to the NCOR/HDAC3 corepressor complex. In case of LXRs the SUMO-binding subunit of the complex was identified to be the actin-binding protein Coronin 2A (CORO2A), at least in the context of TLR4/ NF-kB antagonism [30] .
This may be different in other contexts, such as the negative cross-talk of LXRs with interferon IFNc/ STAT1 also involved SUMOylation but did not depend on NCOR [31] . As a possible cross-talk mechanism different from transrepression SUMOylated LXRs may form a complex with STAT1 that is unable to associate with regulatory regions of selective IFNc-induced genes. Alternatively, the subunit-silencing mediator of thyroid and retinoid receptors (SMRT, also NCOR2) may be responsible for transrepression of IFN responses. SMRT and NCOR have nonredundant functions in controlling proinflammatory gene expression, and treatment with IFNc resulted in the release of SMRT (but not NCOR) from some selective genes [32, 33] .
There are several open issues regarding the LXR/ PPARc transrepression pathways in macrophages. Is receptor SUMOylation ultimately required in vivo (SUMO-mutant LXR mice have not yet been generated)? Are there alternative SUMO-independent antiinflammatory pathways, such as those described for GR? What is the role of RXR, the ultimate heterodimer partner of LXRs and PPARc, that occupies many macrophage enhancers of both metabolic and inflammatory genes [34] and has been shown to be specifically required for the suppression of type I IFN signaling [35, 36] ?
One more recent study has re-evaluated the SUMOdependent transrepression mechanism in case of LXRs and discovered an alternative anti-inflammatory pathway depending on LXR/RXR activation [37] . Cultured macrophages that only expressed SUMOdeficient LXR mutants could still inhibit TLR activation, but the anti-inflammatory function of LXRs was abolished when major RXR isoforms were depleted. The authors concluded that LXR/RXR activation is required, and identified the classic target gene Abca1 (encoding the membrane cholesterol transporter ABCA1) as a component of the alternative pathway. As a proof, LXR activation by ligands could no longer antagonize TLR2/4/9 activation in macrophages derived from Abca1-deficient knockout (ko) mice. Evidence was provided that ABCA1-dependent changes in the membrane lipid composition disrupt the recruitment of the signaling components MyD88 and TRAF6, thereby inhibiting the activation of down-stream NF-kB target genes. The LXR-ABCA1 pathway is of further interest as another LXR corepressor termed NCOA5 was described to repress ABCA1 expression and cholesterol efflux via TLR3 cross-talk [38] . Potentially, alterations in the expression and function of multiple LXR corepressors, some of which may be associated with metabolic inflammatory diseases, could impact on the expression of ABCA1 and thereby affect the anti-inflammatory capacity of LXRs and their ligands.
Despite these seemingly contradictory findings, there are other studies supporting the repressive role of SUMOylation in macrophages, particularly in antiinflammatory cross-talk. Dejean and coworkers have recently generated macrophage-specific Ubc9 ko mice [39] . Ubc9 is the only E2-conjugating enzyme required for substrate conjugation of all SUMO isoforms, therefore Ubc9-deficient macrophages should be deficient in SUMOylation. Ubc9 ko mice displayed an upregulation of NF-kB target genes and specifically a type I IFN-like signature. Although this was not directly addressed in the study, the further employment of this or related SUMO-deficient mouse models [40] should allow reinvestigating the involvement of SUMO in anti-inflammatory nuclear receptor repression.
Repression at macrophage enhancers: eRNAs and corepressors in search for function
As evident from a number of recent studies, the combined ChIP-seq analysis of histone marks has been proven to provide precise information about the macrophage epigenome and its dynamics [4, 5, 7, 31, 32, [41] [42] [43] . Depending on the distance to the transcription start sites (TSS) and the presence of specific histone modifications, these regulatory regions are classified into promoters, proximal (1-2 kb) to the TSS and marked by H3K4me3, and enhancers, located tens to hundreds of kb distal to the TSS and marked by H3K4me1. Active promoters and enhancers are further marked by H3K27ac. The recent appreciation of the crucial role that enhancers and chromatin features play in macrophage biology has caused a shift of transcription research away from classic promoter-focused studies (e.g., reporter assays using isolated TF-binding regions). The drawback is that many of those initial promoter studies are difficult to interpret today without integrating the regulatory enhancers that are linked to the expression of a given inflammatory gene in vivo.
The molecular events that occur at promoters and enhancers are functionally very similar [44] . They assemble the same transcriptional machinery (RNA pol2, TFs, coregulators), produce short noncoding RNAs (i.e., eRNAs at enhancers), and communicate with each other to regulate transcription. Enhancers and the TFs/coregulators that bind them play a particular role in specifying macrophage lineages, subpopulations and responses to signals and the tissue environment. However, promoters and enhancers are also sufficiently distinct in terms of the cis-regulatory elements that control the binding of diverse TFs, coregulators and chromatin modifiers, and components of the basal transcription machinery, along with different chromatin features.
ChIP-seq data for a yet limited number of TFs and coregulators suggest a high level of co-occupancy at macrophage enhancers, but the presence of a factor or a combination of factors is not a safe predictor of whether and how the activity of adjacent genes will be affected. Up-regulation of enhancer activity (increase in H3K27ac and eRNA levels) along with gene expression (mRNA), and the concomitant release of corepressors in response to signaling would provide direct evidence that a given enhancer is repressed prior to signaling, but such data are not yet available. Further complicating is the notion that TFs are found also at enhancers that do not contain direct DNA-binding motifs for these factors, suggesting recruitment via other TFs and extensive cross-talk. Moreover, how many TFs and coregulators bind to a specific macrophage enhancer is largely unknown. Estimates based on the available ChIP-seq data (some high-throughput efforts) suggest dozens of TFs and hundreds coregulators to be involved [10, 11, 23] . Currently, the most limiting factor is the lack of high-quality antibodies suitable for ChIP-seq analysis, along with the requirement of large amounts of chromatin (~50-200 million cells per ChIP of one TF).
Enhancer-associated noncoding RNAs (eRNAs) attract much attention as their study helps to understand how signal-specific enhancers cooperate with each other and with promoters to regulate transcription in macrophages [44] . While the precise function of eRNAs is still debated, data support that the local synthesis of eRNAs correlates with the mRNA expression of controlled genes (not only adjacent but also over large distances > 100 kb) and with specific chromatin modifications ('enhancer' marks such as H3K4me1, H3K27ac). A number of studies have analyzed eRNA expression in macrophages directly employing the global run-on (GRO)-seq method that captures nascent RNA synthesis, thus both mRNA and short-lived noncoding RNAS such as eRNAs [43, 45, 46] .
One of these studies indicates that the expression of specific inflammatory eRNAs in mouse BMDMs might be controlled by the nuclear receptor Rev-Erb [47] (illustrated in Fig. 2 ). The study revealed that Rev-Erbbinding sites are mostly found in distal enhancers that control the expression of inflammatory genes (e.g., Mmp9, Cx3cr1). A majority of genes were up-regulated in macrophages lacking the two Rev-Erb proteins (derived from Rev-Erb a and b double-ko mice), suggesting Rev-Erbs to repress these genes. Support for the repressor role comes from additional studies showing that Rev-Erb a controls the circadian regulation of inflammatory cytokine expression (e.g., IL-6) and responses to tissue damage signals and wound repair in macrophages [48, 49] .
How does Rev-Erb repress enhancer activity? It was known that Rev-Erb functions as a transcriptional repressor by recruiting the NCOR-HDAC3 complex [50] .
Although not yet directly addressed, it is likely that the regulation of eRNA expression and enhancer function in macrophages requires the repressive action of the HDAC3 corepressor complex. Indeed, ChIP-seq data suggest that core subunits of the complex occupy a [32, [51] [52] [53] . GRO-seq analysis from macrophages deficient for each of these subunits would be needed to determine which eRNAs and enhancers are directly regulated. So far, the only data available are from NCOR ko macrophages, which surprisingly revealed a down-regulation of eRNA expression (along with gene expression), as compared to wild-type macrophages [52] . These seemingly puzzling results are discussed further below, but a simple explanation could be that not NCOR but its homolog SMRT acts as the Rev-Erb-associated subunit in macrophages.
Further evidence supporting a role of the corepressor complex at enhancers comes from the study of the core subunit G protein pathway suppressor 2 (GPS2) [32] . In GPS2-deficient macrophages, the up-regulation of inflammatory genes such as Ccl2 correlated with the increase in the activity mark H3K27Ac at nearby enhancers (illustrated in Fig. 2) . However, only a subfraction of enhancers that were occupied by GPS2, along with the complex, and adjacent genes were altered upon depletion of GPS2, raising the question of what distinguishes functional (complex-dependent) from nonfunctional (complex independent) enhancers. Possibly, the direct analysis of eRNA expression in these models will provide answers. So far, we can only speculate that the presence of corepressor complexes, along with other coregulators and TFs at inflammatory enhancer 'hot spots' [23] prior to activation ensures tightly controlled and reversible transcriptional responses to different signaling inputs.
While the above examples have been linked to repression of M1-like macrophage phenotypes, a recent study revealed insights into the role of IFNc in repressing M2-like phenotypes [54] . The authors used a combination of transcriptomic and epigenomic approaches to analyze chromatin accessibility, histone modifications, TF binding, and gene expression in IFNc-primed human macrophages. The data revealed that the TF MAF (musculoaponeurotic fibrosarcoma oncogene homolog) regulates the macrophage enhancer landscape and is suppressed by IFNc. Intriguingly, genes associated with MAF-regulated enhancers were suppressed in macrophages isolated from rheumatoid arthritis patients, revealing a disease-associated 'enhancer signature' of IFNc repression [54] .
Repression at the step of transcriptional elongation-an undervalued key feature of inflammatory gene expression Inducible transcriptional programs in macrophages, such as those induced by TLR4 activation, have been classified into primary and secondary response genes (PRGs and SRGs) [9, 55] , alternatively referred to as immediate early (I/E) and late (L) genes [45] . Many key inflammatory genes (e.g., Ccl2, Tnfa, Mmp12) are PRGs that are controlled by a two-step activation process in which signalindependent TFs (e.g., ETS/PU.1, C/EBPs) establish basal transcription that is amplified by signal-dependent TFs (e.g., NF-kB, AP-1, IRFs) [45] .
An intriguing finding was that corepressors (NCOR/ HDAC3, CORREST/HDAC1) are present at the promoters of PRG 0 s but not SRG 0 s in the basal (unstimulated) state [55] . Thus, corepressors probably play a role in establishing a permissive chromatin structure that predisposes these genes for the rapid induction in response to inflammatory signals. A second intriguing observation was that most PRG's/I/E genes, in contrast to SRGs, have preassembled 'paused' RNA polymerase II and positive histone marks at their promoters in the basal state. It has been therefore postulated that induction of many PRGs is controlled at the level of transcriptional elongation [55, 56] . This idea was subsequently confirmed and extended using sophisticated quantitative approaches, demonstrating that TLR4 signaling increases both the rates of transcriptional initiation and elongation at early PRGs [45] .
Independent work has revealed that TFs and corepressors different from NCOR/COREST complexes also modulate this step in the transcriptional process. The GR is a paradigm for a ligand-activated TF that interferes with inflammatory gene transcription via transrepression of both initiation and elongation [25, [56] [57] [58] . GR tethers to inflammatory TFs such as NF-kB and AP-1, and forms a repressive complex with GRIP1 (a member of the NCOA family, also known as NCOA2, TIF2, SRC2). Although it has been proposed that GR transrepression in macrophages does not involve NCOR or SMRT corepressor complexes [58] , it does at least in other cell types, along with the requirement for GR-SUMOylation [59] . Interestingly, the GR-GRIP1 complex inhibits Pol II elongation by blocking the recruitment of the key component PTEFb/BRD4 [57] . This type of 'elongation repression' is not unique to GRIP1 as it was more recently also described for the transcriptional repressor Hes1 [60] . As noted for both Gr/GRIP1 and HES1, unique subgroups of inflammatory genes were inhibited by this mechanism, while others were repressed at the initiation step or unaffected, consistent with the distinct phenotypes of the corresponding ko macrophages [60, 61] .
A related intriguing finding deals with the role of HDACs in transcriptional elongation and helps resolving some of the controversies regarding the role Based on a combination of ChIP-seq, GRO-seq, and small-molecule inhibitors, a recent report has demonstrated that HDACs unexpectedly stimulate, rather than repress, transcriptional elongation and eRNA synthesis [62] . Consistently, HDAC inhibitors reduce enhancer activity. While the nonhistone-acetylated substrates that probably account for the positive role of HDACs in elongation remain unknown, the mechanism has to be taken into consideration when interpreting the phenotype of HDAC3-deficient macrophages. Given that HDAC3 activity requires NCOR as an 'activating cofactor' [63] , it is consistent that the NCOR ko phenotype showed also reduced elongation rates and eRNA production in macrophages [52] . The requirement of HDACs for eRNA production could perhaps be one of the reasons why HDAC-containing 'corepressor' complexes are found at active enhancers.
Multiple pro-and anti-inflammatory macrophage pathways involve 'one' fundamental corepressor complex: evidence for functional separate subcomplexes
As judged from the currently available data, it is striking that many of today's well-characterized macrophage repression pathways involve one fundamental corepressor complex, illustrated in Fig. 2 . The complex is built up by the core subunits HDAC3, NCOR (also known as N-CoR, NCOR1), SMRT (also known as NCOR2), GPS2, and transducin b1-related proteins (TBLR1/TBL1) [64] [65] [66] and integrates in a contextdependent manner with additional subunits such as the actin-binding protein Coronin 2A [30] and lysine demethylase KDM4A [67] . The first complex subunits were identified more than two decades ago based on its association with repressing nuclear receptors, and the complex has since then been linked to a variety of additional TF families and signaling pathways in different contexts [18] . In macrophages and other types of immune cells, the complex has emerged as a crucial integrator of metabolic and inflammatory pathways [12] , some of which are altered in metabolic inflammatory diseases [32, 68] . Therefore, not surprisingly a variety of corepressor pathways in macrophages appear to be linked to the oxysterol receptor LXR. LXR transrepression requires the NCOR and CORO2A subunits [30] , as discussed above. The regulation of LXRdependent cholesterol transport via ABCG1 also requires the subunits GPS2/KDM4A that perhaps additionally modulates PPARc activation [67, 69] .
Evidence for pro-and anti-inflammatory functions of NCOR and HDAC3
Nuclear receptor corepressor seems to repress ABCA1 along with other LXR-regulated genes responsible for the synthesis of anti-inflammatory x-3 fatty acids (i.e., Abca1, Elovl5, Fads2, Fasn, Scd1, and Scd2), thus a consequence is an anti-inflammatory macrophage NCOR ko phenotype with up-regulation of x-3 fatty acids that in turn repress NF-kB (not AP-1) activation [52] . Another implication of the NCOR results was that the NCOR-related subunit SMRT did not compensate for repressing LXR, although there was no previous indication from in vitro work that the nuclear receptor-binding specificities were substantially different between NCOR and SMRT. While macrophagespecific ko mice for SMRT (also NCOR2) have not yet been reported, the SMRT/NCOR cistrome in macrophages has been identified by ChIP-seq and revealed extensive overlap with Bcl-6 but poorly with nuclear receptors [51] . The identification of SMRT/ NCOR as a macrophage corepressor for Bcl-6 complements earlier work demonstrating that Bcl-6 is a transcriptional repressor by antagonizing NF-kB activation. Overall, combined data imply that in case of the inflammatory TF Bcl6, SMRT and NCOR share the target and the task to corepress, while in case of the metabolic TF LXR they do not.
As for NCOR, it was surprising that macrophage HDAC3 ko phenotypes were anti-inflammatory in two independent studies [53, 70] . While the possible involvement of the LXR/omega-3 fatty acid pathway along with high-fat diet treatment was not analyzed in these studies (in fact, LXR target genes were not identified to be up-regulated in HDAC3 ko macrophages), HDAC3 was shown to be required for the LPS or IFN induction of hundreds of proinflammatory genes. The requirement of HDAC3 for LPS/TLR4 responses, also observed in a number of earlier macrophage studies, seemed surprising given the assumed repressive role of HDAC3 as part of the complex. Indeed, in another study HDAC3 and NCOR were shown to assemble a repressive complex via the NF-kB subunit p50, necessary for the TLR tolerance phenomena where sustained TLR4 activation represses inflammatory gene expression [71] . There are a number of studies offering possible solutions to this controversy, but none of these has been tested in the macrophage context. For example, HDAC3/RPD3 functions in transcriptional elongation-coupled activation and might be even required for eRNA synthesis at H3K27Ac labeled active enhancers [62] Independently of the anti-inflammatory M1 phenotype, HDAC3-deficient macrophages showed an alternative M2-like phenotype in the absence of external stimuli and were hyper-responsive to IL-4 [53] . Thus, a likely role of HDAC3 is to repress M2 activation, perhaps by inhibiting STAT6/PPARc activities [73] . Evidence was further provided that HDAC3 deacetylates active histone marks (e.g., H3K27ac) in the regulatory regions of IL-4-induced genes. One would assume that this mechanism requires the catalytic activity of HDAC3, although this is dispensable in other contexts, for example, in liver circadian gene expression [50] . If required, it is tempting to speculate that the pharmacological blockade of HDAC3 activity could be of therapeutic value. Indeed, following exposure to Schistosoma mansoni eggs, an in vivo model of Th2 cytokine-mediated disease that is limited by M2 macrophages, lung inflammation was improved in mice lacking HDAC3 in macrophages. Overall, the involvement of the HDAC3 in both M1 and M2 macrophage pathways points at a perhaps integrative role of the corepressor complex in mediating the documented extensive epigenomic and transcriptomic cross-talk between these pathways [41] .
Evidence for anti-inflammatory functions of GPS2 and SMRT
In contrast to the NCOR and HDAC3 models, macrophage GPS2 ko mice displayed a proinflammatory phenotype [32] . Notably, GPS2 ko mice have several hallmarks of metaflammation [19] and thus provide the opportunity to dissect underlying mechanisms: (a) chronic elevated low-level inflammation under basic/ chow diet conditions, (b) accelerated adipose tissue inflammation and macrophage infiltration, and (c) development of systemic insulin resistance under dietinduced obesity conditions. The phenotype is consistent with the genomic features of the GPS2-containing repression pathway and involves direct repression of the AP-1 subunit c-Jun. AP-1 sites are among the most frequent TF-binding sites in macrophage enhancers, and GPS2/AP-1 colocalized at inflammatory enhancers [19] . Earlier work had elucidated in detail the essential role of c-Jun in TLR4 signaling and Ccl2 regulation and suggested direct interactions with HDAC3 and SMRT/ NCOR. Thus, cooperative interactions with various subunits of the corepressor complex may contribute to its key role in repressing AP-1-dependent inflammatory genes in macrophages. Interestingly, the LXR x-3 fatty acid pathway was not affected by GPS2 depletion, suggesting that NCOR and GPS2 act separately, perhaps in subcomplexes (discussed further below). In addition to the genomic mechanism, it has been suggested that GPS2 might interfere with cytoplasmic inflammatory signaling by inhibiting JNK activation [66, 74] .
The GPS2 ko study [32] revealed additional insights into the possible functional co-operation of individual corepressor complex subunits with each other. Gene expression analysis in combination with the comparative RNAi depletion of NCOR, SMRT, and GPS2 from macrophages identified a tight functional cooperation of GPS2 with SMRT, but not with NCOR or HDAC3, to repress inflammation. This provides mechanistic explanations for the distinct roles and MKO phenotypes of GPS2 and NCOR in macrophage inflammation. Selectivity for SMRT (over NCOR/ HDAC3) and, as the data also suggest, for c-Jun/AP-1 (over additional inflammatory TFs tested) further specify the anti-inflammatory capacity of GPS2-containing complexes. The proposal of two functional sub-complexes, that is, GPS2/SMRT (anti-inflammatory) versus NCOR/HDAC3 (proinflammatory), clarified the seemingly contradictory phenotypes of the corresponding ko models.
The data put forward the concept that functional subcomplexes exist within what is commonly thought to function as 'one corepressor complex'. Subcomplex specificities would allow controlling transcription of distinct gene clusters in response to a variety of signals and likely result from differential interactions with TFs, coregulators, and chromatin components (e.g., histones, enhancers). Considering these aspects may help to further dissect macrophage gene expression clusters that are possibly controlled by different subcomplex combinations along with key TFs. However, the concept also raises questions which are impossible to answer without further experimental evaluation. For example, the determinants of functional subcomplex formation are unknown. GPS2 has been biochemically found along with NCOR and SMRT in the complex [66] , although it cannot be excluded that there might be preference for SMRT over NCOR [64] . A more likely answer lies in the different TF selectivity along with different TF combinations present at individual enhancers in vivo. PTMs are other strong candidates that specify PPIs among the complex subunits in a likely signal-regulated manner [75] . Loss of GPS2 in obese humans and mice: how corepressor complex dysfunction can cause epigenome alterations and metaflammation, and vice versa
Research into human disease mechanisms greatly benefits from clinical correlation data as they can provide the starting hypothesis that subsequently can be rigorously tested and validated in mice and cellular models. This is exemplified by Fan et al. [32] who initially aimed to explore which coregulators critically modulate metaflammation in the context of obesity. In obese humans and mice, adipose tissue macrophages are a major source of inflammatory chemokines and cytokines. The resulting state of low-grade metabolic inflammation (metaflammation) interferes with adipose tissue metabolism and triggers insulin resistance. Gene expression analysis in macrophages isolated from adipose tissue of three different human populations revealed a significant decrease in GPS2, but not of any other corepressor complex subunit, in adipose tissue macrophages of diabetic subjects. Reduced GPS2 levels were correlated with an increase in markers of inflammation (notably Ccl2, which subsequently was characterized as a major GPS2-regulated gene) and insulin resistance (HOMA-IR or HbA1c). These correlations are of importance because they point at the possibility that inappropriate GPS2 function could be linked to macrophage pathways that drive adipose tissue dysfunction and insulin resistance. Experiments in mice and cultured macrophages identified a causal role of loss-of-GPS2 in driving the disease process. The data indicated that alterations of macrophage GPS2 pathways are conserved between humans and mice and thus might represent attractive targets for therapeutic intervention. Since GPS2 functions within an anti-inflammatory corepressor subcomplex to modify the macrophage epigenome, the study [17] provides a unique example for how alterations of an epigenomic coregulator can drive metaflammatory disease pathways toward type 2 diabetes. A model emphasizing these key features is proposed in Fig. 3 .
G protein pathway suppressor 2 is unlikely to be the only factor controlling the onset of metaflammation but the data suggest it to be an important contributor at the epigenomic level, as its loss accelerates metaflammation. GPS2 directly communicates with cJun (AP-1), but it may be dispensable for other inflammatory TFs such as NF-kB or IRFs. In line with this, a classic NF-kB target gene Tnfa was not repressed by the GPS2-containing corepressor subcomplex in any of the macrophage populations tested [32] . Therefore, in wild-type mice and in humans, diet-induced metaflammation may be initiated by both GPS2-independent (e.g., TNF activation) and GPS2-dependent (e.g., TLR4 activation) pathways but gets worse as a consequence of GPS2 down-regulation. This is clearly supported by the phenotype of the macrophage-specific ko mice upon high-fat diet treatment, and in particular by kinetic analysis demonstrating that loss of GPS2 resulted in increased metaflammation already within 4 weeks of treatment.
To evaluate the capacity of GPS2 to reverse adipose tissue inflammation and improve whole body insulin sensitivity, the authors went on to transplant bone marrow overexpressing GFP or GPS2 in irradiated Ob/Ob (leptin ko) or C57BL6/J mice, followed by 10 weeks of high-fat diet in the latter model [32] . In these studies, GPS2 was modestly overexpressed (threefold increased mRNA) in adipose tissue macrophages. The experiments revealed that GPS2 overexpression in both BMT models significantly reduced the inflammation in the adipose tissue and in liver, inhibited adipose macrophage infiltration and liver lipid accumulation, and improved systemic glucose control. These results provide independent in vivo confirmation for the causal relationship between GPS2 levels in macrophages, adipose tissue inflammation, and insulin resistance. They also exemplify what could be of future therapeutic value, namely that boosting GPS2 levels/ function has the potential to restore the anti-inflammatory capacity of the GPS2-containing subcomplex and thereby to improve metabolic disease.
Context matters: how IRF5 activation versus repression pathways determine macrophage M1 versus M2 polarization
Interferon regulatory factors were originally described as regulators of type I IFN expression and signaling. However, it is now well established that they have additional important functions, including the regulation of macrophage activation [76] . There are nine IRFs in mammals that bind to consensus ISRE sequences with a remarkable specificity in terms of the regulation of gene expression, as shown by the specific phenotypes of mice with different IRF gene knockouts [76] . IRF4 was shown to specifically regulate M2 macrophage polarization in response to parasites or the fungal cell wall component chitin. This pathway involves the histone demethylase JMJD3 (KDM6B), which functions by removing an inhibitory histone modification H3K27me3 [77] , as further outlined below. IL-4 has also been shown to induce IRF4 [78] , which indicates that STAT6-mediated IRF4 expression might reinforce the M2 phenotype. Recent studies have described a role for IRF5 in the M1 polarization of macrophages in human and mice [79, 80] . IRF5 has previously been shown to be required for optimal expression of IL-12 and proinflammatory cytokines in mice. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-polarized macrophages from human peripheral blood have been used to demonstrate the role of IRF5 in human macrophage polarization [80] . However, GM-CSFinduced human macrophages have an M1-like phenotype, with increased expression of IL-12 and proinflammatory cytokines, the ability to activate TH1 cell immune responses and decreased expression of IL-10. These characteristics were increased by the overexpression of IRF5 and inhibited by a small interfering RNA targeting endogenous IRF5 expression. IRF5 is directly recruited to gene promoters associated with the M1 phenotype (including IL12b), but it represses IL10, probably also by binding to an ISRE in the gene promoter [80] . A similar approach confirmed this mechanism in human adipose tissue macrophages [79] and extended it by showing that IRF5 represses IL10 and TGFb, indicating that the protective phenotype observed in IRF5 ko mice is largely due to the derepression of these genes.
An interesting aspect of these studies is the dual function of IRF5 in activating M1 genes while repressing M2 genes by binding to similar cis-acting elements in the gene promoters. This indicates that there might Fig. 3 . Loss-of-corepressor-dependent alterations of the macrophage epigenome trigger insulin resistance in obese mice and humans. A functional GPS2-SMRT subcomplex occupies enhancers and promoters of pro-inflammatory genes, which undergo epigenomic changes (e.g., H3K27ac levels) when GPS2 is reduced (obese humans and mice) or lost (ko mice). In addition to derepression, the responses to acute (LPS) and metabolic (palmitate, high-fat diet) signals were enhanced upon loss-of-GPS2. Thus, obesity-induced alterations in adipose tissue macrophages perhaps establish an epigenomic memory that accelerates metaflammation states toward the development of insulin resistance and type 2 diabetes. be different collaborating TFs and/or coregulators for IRF5 at M1 versus M2 gene promoters, and that these factors might eventually direct distinct functional outcomes. A recent study demonstrated that NF-jB RelA (p65) assists IRF5 in binding to DNA, and the two TFs set up a unique 'inflammatory' IRF5:RelA cistrome [81] . This mechanism seems key in the regulation of M1 macrophage genes. Regarding the repressive action, which is more clinically relevant, more work is definitively needed to identify partners of IRF5. The interactome of IRF5 is rapidly expanding [82] and it is possible that other yet to be identified TFs may aid to recruit IRF5 to other gene promoters in the absence of RelA binding. Overall, the reciprocal regulation of M1 and M2 genes by the same TFs (as discussed here for IRF5), and coregulators (as discussed before for HDAC3) seems to be a common theme in macrophage polarization and is illustrated in Fig. 4 .
In addition, it is of medical interest that human genome-wide association studies identified IRF5 as a genetic risk factor for many autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease [83] [84] [85] [86] . More recently, alterations of IRF5 levels were also linked to obesity and its comorbidities such as nonalcoholic liver disease (NASH) and type 2 diabetes [79, 87] . Interestingly, protective effects seen in IRF5 ko mice are due to the defect of its repressive activity, emphasizing therapeutic opportunities via manipulating IRF activity, in line with recent attempts to develop decoy peptide inhibitors [88] .
Repressive chromatin structure and type 2 diabetes: the example of the chromatin modifier JMJD3 (KDM6B) in macrophages Aberrant epigenetic reprogramming occurs frequently in the development of diseases. Histone H3 lysine 27 trimethylation (H3K27me3) exerts a repressive epigenetic mark on a large number of genes. UTX and JMJD3 are the only histone demethylases which activate gene expression via demethylating H3K27me3 to H3K27me2 or H3K27me1. Inflammatory pathways involve the histone demethylase JMJD3 (also known as KDM6B), which is induced by LPS/TLR4 signaling and removes an inhibitory histone modification, H3K27me3 [77] . Proinflammatory TLR4 gene activation was decreased in JMJD3-deficient macrophages [89] . In line with these results, targeting JMJD3 H3K27me3 demethylases with small-molecule inhibitors impairs inflammatory responses in human primary macrophages and could thus be of high pharmacological interest for the treatment of inflammatory diseases [90] . Although JMJD3 is induced by proinflammatory stimuli and targets a major repressive chromatin mark found at thousands of promoters and enhancers, its role in M1 macrophages appears limited to fine-tuning the expression of a few hundred genes (such as Il12b and Ccl5) in response to LPS [89] . As discussed above for HDACs, JMJD3 possibly acts at several steps in transcription including elongation, and histone-modifying activity may not be the only determinant of JMJD3 0 s function. Conversely, the absence of JMJD3 completely blocks the induction of M2 macrophages in mice challenged with helminths or chitin [91] , indicating that the role of JMJD3 is greater in M2 than in M1 macrophages. Importantly, although there is some controversy in this regard, M2 macrophage polarization in response to IL-4 seems to be largely independent of JMJD3 [91] . This indicates that the induction of M2 macrophages in response to alternative stimuli follows different routes. JMJD3 seems to function by controlling expression of the TF IRF4, which in turn is required for M2 polarization of macrophages. Although this pathway is strongly supported by human genetics data, the molecular and mechanistic details are still unclear. Specifically, it is not known how inflammatory signals affect JMJD3 expression and function and how JMJD3 would be selectively recruited to gene promoters and enhancers, given its limited set of regulated genes. The dual role of JMJD3 in both M1 and M2 polarization is not necessarily enigmatic and probably reflects the need for JMJD3 to enable responses to various environmental stimuli. Overall, JMJD3 actions is in addition to HDAC3 another example for a chromatin modifier that integrates responses to different inflammatory stimuli at the epigenomic level, including IL-4, receptor activator of nuclear factor kappa B ligand, macrophage colonystimulating factor, SAA, and LPS/TLR4 signaling. Epigenetic signatures differ in chronic inflammatory disease states such as type 2 diabetes, and Jmjd3 represents one of the few examples for an epigenetic modifier that could be directly involved in these alterations in macrophages. Gallager et al. revealed a potential new role for JMJD3 in modulating IL-12 expression by macrophages in the setting of T2D. This is in agreement with a recent study where treatment of macrophages with a selective JMJD3 inhibitor led to alterations in proinflammatory cytokines [90] . However, it is not possible to determine the degree to which the observed changes in histone methylation are due to nutrient overconsumption and obesity, insulin resistance, or hyperglycemia. A recent clinical study revealed that alterations in DNA methylation are predominantly the consequence of adiposity, rather than the cause [92] . The methylation loci identified genes involved in lipid and lipoprotein metabolism, substrate transport, and inflammatory pathways [92] . Interestingly, this study also suggested that the disturbances in DNA methylation predict future development of type 2 diabetes, which provide new insights into the biologic pathways influenced by adiposity, and may enable development of new strategies for prediction and prevention of type 2 diabetes and other adverse clinical consequences of obesity. In line with this report, JMJD3 seems to be a potential candidate for macrophage polarization and type 2 diabetes onset [93] . Further work is needed to investigate how changes in epigenetic signatures in metabolic diseases are controlled by JMJD3 and how these chromatin modifications are reversible upon JMJD3 inhibition.
Other examples for how the study of repression pathways revealed putative mechanisms underlying metabolicinflammatory diseases
The study of histone deacetylase HDAC4 ko mice has shed light on the relationship between cAMP signaling and inflammation control in the setting of obesity [94] . It was known that the second messenger cAMP attenuates macrophage inflammation in the setting of overnutrition. In search for underlying mechanisms, HDAC4 activation in response to leptin-dependent cAMP signaling was identified as the responsible transcriptional mediator. Specifically, the study demonstrates that cAMP stimulates activity and import of HDAC4 to the nucleus, where it acts as a corepressor of NF-kB at inflammatory genes. Intriguingly, the HDAC4 ko mouse model is relevant for testing LXR transrepression in vivo. HDAC4 was earlier demonstrated to be required for LXR modification by SUMO-2 [29, 30, 40] . Thus, it would be most interesting to test whether SUMO-2-dependent LXR transrepression is abolished in the macrophage-specific HDAC4 ko mice.
The orphan receptor small heterodimer partner (SHP, NR0B2) is best known as an atypical member of the nuclear receptor family that acquired the function of a corepressor by inhibiting the activity of other nuclear receptors, particularly in the liver [95] . Yuk et al. [96] showed that SHP is also expressed in macrophages and functions as an inhibitor of TLR4 activation. Mechanistically, the study identified two distinct regulatory actions. First, by acting as a nuclear corepressor, SHP docks to and represses the NF-kB subunit p65. Second, SHP interferes in the cytoplasm with the ubiquitination of the adaptor protein TRAF6, a regulatory component of membrane signaling pathways toward NF-kB. This cytoplasmic mechanism appears closely related to the one reported for the corepressor complex subunit GPS2, which inhibits TRAF2 [74] . Since GPS2 interacts with SHP [95] , it remains possible that these mechanisms are linked to each other.
The study of activating transcription factor 3 (ATF3), a member of the CREB/ATF family of TFs, has revealed insights into the mechanisms underlying the anti-inflammatory effects of high-density lipoprotein (HDL). ATF3 was known to be induced by LPS and to act as a negative regulator of TLR4 activation, likely as part of a feedback loop [97] . Subsequently, it was shown that ATF3 mediates anti-inflammatory reprogramming of macrophages in response to HDL treatment in vitro and in vivo [98] . HDL induces ATF3 expression, which in turn acts as a repressor of proinflammatory cytokine gene expression (e.g., IL6, TNF) by interfering with the activation of NF-kB and AP-1, the key activators that often co-occupy proinflammatory promoters and enhancers. The ATF3 pathway may explain the broad anti-inflammatory effects of HDL not only in hypercholesterolemia and atherosclerosis but presumably also in a variety of other inflammatory diseases that may benefit from HDL-based therapies.
As a last example, the nuclear receptor Nr4a1 (Nurr77), along with its corepressor COREST, was shown to inhibit neuroinflammation by specifically repressing the Th gene (encoding tyrosine hydroxylase, the ratelimiting enzyme in catecholamine biosynthesis) in CNS-recruited macrophages [99] . Myeloid-specific Nr4a1 ko mice showed enhanced neuroinflammation and exacerbation of experimental autoimmune encephalomyelitis (a mouse model of multiple sclerosis), suggesting that synthetic NURR77 ligands could be of therapeutic interest.
Conclusions and perspectives
In this review, the components and specificity determinants governing repression in macrophages described provide only a limited snapshot of a very complex and dynamic mechanism that we are only beginning to understand. Deeper qualitative and quantitative insights would require the comparative high-throughput analysis of dozens of TFs along with multiple relevant corepressors/complex subunits in different signaling situations and in different macrophage models, including tissue macrophages from human sources. Specifically, advance in technology must overcome current difficulties to reproducibly enrich corepressors by ChIP-seq in macrophages. ChIP-Seq of these proteins (that do not directly bind to DNA) remains challenging and requires high-quality antibodies, refined crosslinking procedures, and larger amounts of cells than the analysis of chromatin marks and TFs. For example, ChIP-seq data have been reported so far only once for NCOR, SMRT, HDAC3, and GPS2, along with few key inflammatory TFs such as PU.1, p65, and c-Jun, from mouse BMDMs. Thus, information from other types of tissue macrophages including human adipose tissue macrophages is not yet available.
Open issues relate also to the interpretation of ChIP-seq data. Currently available data indicate that many TFs and coregulators (i.e., whatever protein is possible to analyze, only few so far) co-occupy most inflammatory enhancers in macrophages, while depletion of any of these factors seems to affect only a subfraction of genes regulated by those enhancers. In other words, functional requirement for gene expression cannot be predicted at the level of chromatin occupancy but requires lack-of-function studies along with transcriptome analysis. Moreover, DNA sequence motifs for TFs that are found in macrophage enhancers suggest which classes of TFs potentially bind to these regions, yet the specific TFs are largely unknown. For example, enrichment of AP-1 motifs does not indicate which of the many TFs that recognize the motif (e.g., c-jun, junB, ATFs, c-fos, C/EBPs) can bind. Extensive ChIP-Seq data for all family members, along with chromatin-proteomics data (such as RIME) would be required to map the full TF composition in a spatial-temporal fashion. These genomic and epigenomic efforts have to be complemented by in vivo disease models including macrophage-specific ko mice and humanized models. Currently, the number of in vivo well-characterized macrophage TFs and corepressors, both using genome-wide approaches and macrophage-specific ko mice, are still very limited and likely represent only a minor fraction of all functional chromatin-bound regulatory factors.
Other concerns are related to the clinical relevance of current data and possible disease mechanisms, mostly derived from cultured macrophages and mouse models, in humans. So far, clinical epigenetics data are largely limited to the genome-wide study of DNA methylation (the methylome), which requires less material compared to the analysis of chromatin and regulatory proteins. Future efforts have to dissect the largely enigmatic relationship of DNA methylation, cis-regulatory elements (enhancers, promoters), histone modifications, and transcriptomes. This will shed light on mechanisms that play roles in the epigenetic manifestation and (possibly) inheritance of metabolic inflammatory diseases, which may involve coregulators as chromatin modifiers.
Despite all concerns, a deeper molecular, physiological, and translational (mouse/human) characterization of macrophage repression pathways promises to reveal novel insights into the role of epigenomic mechanisms underlying macrophage physiology and pathophysiology linked to disease states. This improved knowledge is ultimately needed to implement novel and feasible therapeutic targets and macrophage epigenomics-based strategies for the treatment and prevention of metabolic-inflammatory diseases. For example, future work has to demonstrate whether repressive macrophage enhancers, and the TFs and corepressors that bind them, can be selectively manipulated in vivo with the aim to therapeutically reverse disease states. Such strategies may involve the selective targeting of the corresponding eRNAs and other noncoding RNAs involved in the regulation of repression. Additionally, new generations of nuclear receptor ligands such as selective nuclear receptor modulators may help to stabilize macrophage repression and transrepression pathways, while reducing current undesired effects on metabolism and inflammation. Of interest may also be the employment of epigenetic drugs including smallmolecular inhibitors of histone-modifying enzymes such as deacetylases (HDACi) and demethylases (KDMi). Overall, there is little doubt that any of the above-mentioned future efforts will not only be challenging but also awarding with the expected advancement of scientific knowledge and therapeutic possibilities.
